Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

ExternalLink');" target='_blank' href="http://www.nexavar.com/">www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG.  Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, which includes Cardiology and Primary Care and Specialty Medicine, which includes Hematology, Oncology and Multiple Sclerosis. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a targeted alpha-folate inhibitor, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing.
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 2015 A global continuing medical ... and thyroid disorders in Central and South-East ... a major conference dedicated to these diseases. ... Online , Manage Hypertension Online and ... by EXCEMED - combine the world,s top ...
(Date:7/3/2015)... July 3, 2015 Un ... épidémies que sont l,hypertension, le diabète et les ... plateformes éducatives gratuites et d,une conférence majeure dédiée ... http://photos.prnewswire.com/prnh/20150630/227033 ) , Les formations ... , Prendre en charge l,hypertension en ligne ...
(Date:7/3/2015)... 3, 2015 Der ... bestimmter Abschlussbedingungen eine 100-prozentige Beteiligung am Unternehmen ... Mit dieser Übernahme dringt Lupin in den ... von 765 Mrd. RUB im Jahr 2014 ... gehörte (IMS Health). Seit über einem Jahrzehnt ...
Breaking Medicine Technology:Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 3Lupin übernimmt Biocom aus Russland 2Lupin übernimmt Biocom aus Russland 3
... PITTSBURGH, Oct. 13 BIOSAFE, Inc. , a ... has announced that they are launching in specific markets ... with BIOSAFE (®) . Crosstex, new BIOSAFE-treated Ultra ... VRE, and Staph immediately upon contact, and have further ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced ... 3,000,000 shares of its common stock at a price ... from the sale of shares in this offering, after ... expenses, were approximately $20.9 million. Sangamo intends to use ...
Cached Medicine Technology:BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 2BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 3BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 4Sangamo Announces Closing of Common Stock Offering 2Sangamo Announces Closing of Common Stock Offering 3
(Date:7/3/2015)... ... , ... The Harvest Hope Food Bank will hopefully be getting a large donation ... in the area of Greenville SC are making it their mission to collect as many ... are asking for donations from the public as well. As part of the canned food ...
(Date:7/3/2015)... ... ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. ... To be held from March 4th - 6th, the 2016 (a previous announcement had ... , Designed to take participants from the basic training and fundamentals of nasal surgery ...
(Date:7/3/2015)... ... ... Talcum powder attorneys representing clients in national lawsuits announce the launch of ... Just as the previous version did, the new website will serve as a public ... cancer warning information. The site is routinely updated with news articles on talcum powder ...
(Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness ... where they provide members of the Red Deer community with free fitness training and ... fitness training, games, food, events and entertainment raised thousands of charity dollars and ended ...
(Date:7/2/2015)... ... July 02, 2015 , ... Following the recent report by ... of obese Americans outnumber merely overweight Americans, Samir Becic emphatically declared a war on ... American society right now," Becic said. "We must understand the magnitude of this discovery. ...
Breaking Medicine News(10 mins):Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4
... Contest ... ... -- InSound Medical , manufacturer and developer of Lyric®, the first 100 percent invisible, ... Lyric Hearing Story" Contest. Lyric wearers have the opportunity to win a free year ...
... , SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ ... announced that its board of directors has declared a third quarter 2009 ... equivalent to an annualized dividend of $0.44 per common share. , ... has declared a dividend of $0.46094 per share of the company,s 7.375% ...
... , THOUSAND OAKS, Calif., Sept. 15 ... the Court of Appeals for the Federal Circuit affirmed the ... four Amgen patents (,868, ,698, ,933 and ,422) relating to ... a fifth patent (,349), the Federal Circuit reversed the holding ...
... Approval Provides Important Tool to Fight Pandemic , , ... announced today that it has approved four vaccines against the 2009 H1N1 ... become available, which is expected within the next four weeks. , ... , , "Today,s approval is good news for our ...
... big reason why, researchers say , TUESDAY, Sept. 15 ... the hospital are much less likely to survive than white ... appears to result from the hospital in which black patients ... the researchers said. , "We know that survival after having ...
... , WASHINGTON, Sept. 15 The American ... impact on health care issues conducted by Pulse Opinion Research, LLC, ... of Americans believe that high immigration levels have had an adverse ... Republicans (89%) felt more strongly on the issue, but Democrats ...
Cached Medicine News:Health News:InSound Medical Kicks Off "Tell Us Your Story" Contest 2Health News:BioMed Realty Trust Declares Third Quarter 2009 Common Stock and Preferred Stock Dividends 2Health News:Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product 2Health News:FDA Approves Vaccines for 2009 H1N1 Influenza Virus 2Health News:FDA Approves Vaccines for 2009 H1N1 Influenza Virus 3Health News:Blacks Fare Worse After Cardiac Arrest 2Health News:Blacks Fare Worse After Cardiac Arrest 3Health News:National Poll Finds Most Americans Believe Immigration Adversely Affects the Quality and Cost of Healthcare 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: